Medicinal and aromatic plants and their preparations are used by human beings all over the world. With respect to their legal status, these products are either medicines or foodstuffs, depending on their use and the legal situation in each country. According to the basic European Directives in the pharmaceutical area, medicinal products require pre-marketing approval before gaining access to the market. Documentation of quality, safety, and efficacy as well as respective expert reports are required. Quality requirements for herbal medicinal products include appropriate quality of the raw material (e.g. European Pharmacopoeia, Good Agricultural and Collection Practice), Good Manufacturing Practice and testing on potential contamination (e.g. microbiological purity, heavy metals, aflatoxins, pesticides). Regarding safety and efficacy assessment, in principle for all medicinal products pharmacological and toxicological examinations are requested, and efficacy has to be proven by clinical studies. 
INTRODUCTION
Medicinal and aromatic plants and their preparations belong to the oldest known health-care products that have been used by human beings all over the world. With respect to their legal status, these products are either medicines or food, depending on their use and/or therapeutic indication claims as well as the legal situation in each country.
Regulations on Food and on Medicines
Quality requirements for food cover certain standards (e.g. ISO) and limits for orientation as well as European Directives e.g. on pesticide residues. For heavy metals and aflatoxins national regulations or recommendations exist. However, unlike herbal medicinal products, food and food supplements do not require pre-marketing approval by the competent authority and therefore no proof of quality, efficacy and safety of the product. A European Directive on food supplements has recently been developed stating under which conditions a product is permitted to be marketed as a food supplement. A 14 Regulation on claims for all kinds of food is in preparation.
According to Directive 2001/83/EC which codifies the former Directives 65/65/EEC, 75/318/EEC and 75/319/EEC, pharmaceutical products require pre-marketing approval before gaining access to the market. Requirements for the documentation of quality, safety, and efficacy, the dossier and the expert reports are laid down in Annex I of Directive 2001/83/EC. The EU Member States made different approaches to review herbal medicinal products in order to fulfil these provisions. A detailed overview particularly on the current legal situation for herbal medicinal products in each Member State, the implementation of the requirements of the relevant Council Directives and the actual practices in the assessment of quality, safety and efficacy of these products has been presented in the Study "Herbal Medicinal Products in the European Union" which was carried out by AESGP, the Association of the European Self-Medication Industry, on behalf of the European Commission in 1998. The study has been published in http://pharmacos.eudra.org/F2/pharmacos/comdoc_doc.htm
The Marketing Authorization Procedure
For the achievement of a free movement of medicines within the Common Market of the European Union, a centralized system of marketing authorization, e.g. for new chemical entities, as well as a decentralized system of mutual recognition of marketing authorization decisions has been established. The latter one is considered the appropriate procedure for those herbal medicinal products which are intended to be marketed in more than one Member state of the European Union.
As a general rule, the current decentralised procedure provides the opportunity that the assessment by one national authority is sufficient for subsequent registration in other Member States, thus contributing to facilitate access to the single market. Therefore a marketing authorisation in one Member State ought to be recognised by the competent authorities of the other Member States in principle, unless there are grounds for supposing that the authorisation of the medicinal product concerned may present a risk to public health, with regard to the quality, safety and efficacy of the product.
Within this procedure, the so-called "Summary of Product Characteristics (SPC)" agreed by the first authority is one of the basic elements. It represents the main characteristics of the product e.g. active ingredient, indication, dosage, contra-indications, side-effects, shelf-life, etc.
QUALITY REQUIREMENTS
According to Directive 2001/83/EC relating to medicinal products for human use, for each product a detailed documentation of quality is required, in particular on the raw material and its purity, on the manufacturing process, control of the final product and its stability.
The European Pharmacopoeia
The recognised common standards for the quality of medicines with the objective to ensure their quality are laid down in the European Pharmacopoeia. Besides a large number of monographs on individual substances and plant drugs, general monographs on herbal drugs, herbal drug preparations and herbal teas are available. The general monograph on herbal drugs includes the definition, production, identification and tests, in particular on potential contaminants. The monograph on herbal drug preparations defines those as e.g. comminuted or powdered herbal drugs as well as e.g. extracts and tinctures. The monograph on herbal teas points out recommendations on microbial quality as well as specific requirements for the uniformity of mass of herbal teas in sachets.
Furthermore, the European Pharmacopoeia contains a new general monograph with specific requirements for extracts including a differentiation into three types of extracts: standardised extracts, quantified extracts and extracts defined by the production process. This monograph also describes the following kinds of extracts: liquid extracts, tinctures, soft extracts and dry extracts together with their definition and requirements for tests (e.g. dry residue), storage and labelling.
Good Agricultural and Collection Practice
In order to ensure a high and consistent quality of the raw material, the recommendations on Good Agricultural and Collection Practice should be respected. Such recommendations have been published by Europam, the European Herb Growers' Association in 1998 and later on by the HMPWP (see below), and a respective paper of WHO is under consideration. Based on these recommendations, FAH, the German Medicines Manufacturers' Research Association, has proposed a Standard Operating Procedure to perform an audit in the area of cultivation and collection of medicinal plants.
Tests for Special Impurities
Medicinal plants growing in nature are exposed to biological influences such as damage by insects or pests as well as to influences from the environment such as e.g. heavy metals. For the production of herbal medicinal products containing raw materials of natural origin, specific criteria for purity have to be fulfilled which exceed the drugspecific requirements laid down in individual pharmacopoeia monographs. These criteria mainly comprise microbiological purity, heavy metals, aflatoxins and residues of plant protection products, furthermore, if applicable, tests on ethylene oxide and radioactivity. In addition, extracts have to be examined for residues of solvents which have been used for the extraction process. Their quantity should be limited as far as possible after the concentration and drying procedures.
Microbiological Testing
The general requirements for microbiological purity are laid down in the European Pharmacopoeia, chapter 5.1.4, providing four different categories. For herbal medicinal products mainly categories 3 and 4 are applicable which set limits for different kinds of potential microbial contamination. Category 3A in general covers preparations for oral and rectal administration, category 3B includes certain preparations for oral administration "for which antimicrobial treatment is not feasible" (such as medicinal plants which are not pre-treated). Category 4A describes herbal medicinal products "to which boiling water is added before use" (herbal teas), category 4B covers other herbal medicinal products containing herbal drugs, not extracts.
Heavy Metals
The general monograph on herbal drugs states that a potential risk of heavy metals must be considered and, unless included in an individual monograph, limits may be required if justified. At present, only in few cases limits have been fixed within individual monographs for herbal drugs. Furthermore a general analytical method has been proposed in Pharmeuropa, a scientific journal where draft monographs for the European Pharmacopoeia are published.
As a measure on a national level, the German Ministry of Health sent a "Draft Recommendation for Limits of Heavy Metals in Medicinal Products of Plant and Animal Origin" to the pharmaceutical trade associations in 1991. This draft "Recommendation on Contaminants -Heavy Metals" included limits for plants, parts of plants, oils, fats and waxes of plant origin and products thereof as well as for other products of plant origin, each with reference to the dried matter: lead 5 mg/kg, cadmium 0.2 mg/kg, mercury 0.1 mg/kg with certain exemptions for cadmium.
Aflatoxins
There is no specific regulation on aflatoxins in herbal drugs on a European level. However, the general monograph states that, where necessary, respective limits may be required.
On a national level, a regulation on the prohibition of the use of substances 16 contaminated with aflatoxins in the manufacture of medicinal products was published by the German Ministry of Health in July 2000 and came into force on 1 February 2001. It contains limits for aflatoxin B1 of 2 µg/kg and the total sum of aflatoxins B1, B2, G1 and G2 of 4 µg/kg, furthermore of aflatoxin M1 of 0.05 µg/kg (which is, however, not relevant for material of herbal origin). In addition, the determination of the level of aflatoxins content has to be based on sampling procedures taking into account a potential heterogenic distribution in the material. Future regulations on aflatoxins and ochratoxins are also being discussed within the European Pharmacopoeia Commission. For aflatoxins, the above-mentioned, already established limits are very likely to be set.
Plant Protection Products
In the European Pharmacopoeia, chapter 2.8.13 on "Pesticide Residues", limits for 34 plant protection products are laid down. The limits applying to those substances which are not included in the table but whose presence is assumed, must comply with the European Directives on plant protection products established mainly for the food area and transferred into national laws.
The European Pharmacopoeia monograph furthermore describes how limits for further suspected (in raw material potentially occurring) substances can be calculated using a specific expression which takes into account the acceptable daily intake (according to WHO/FAO), the body mass and the daily dose of the drug. If the drug is intended for the preparation of an extract, a specific extraction factor is used which has to be determined experimentally. According to the European Pharmacopoeia, limits may also be permitted in single cases, particularly when a plant requires a particular cultivation method or when it has a metabolism or a structure that can lead to a higher than normal content of pesticides.
The European Pharmacopoeia monograph includes details on sampling as well as general requirements for analysis of pesticide residues. Specific tests for organochlorine, organophosphorus and pyrethroid insecticides are also available in this monograph. For the next years, a revision of this monographs is planned.
Ethylene Oxide
Since 31 December 1990, the placing on the market and the use of ethylene oxide for the reduction of pathogens in dried herbs intended exclusively for marketing as medicinal products without further processing, is prohibited in Member States of the European Union.
Radioactivity
For the testing of possible radioactive contamination after the accident at the Chernobyl nuclear power plant in May 1986, a regulation demanded maximum radioactive levels in terms of caesium-134 and caesium-137 of 370 Bq/kg for milk products and certain foodstuffs for infants and 600 Bq/kg for all other products concerned, respectively. Later on, several Commission Regulations exempted medicinal plants from this requirement. Although testing on radioactivity is thus no longer legally required, manufacturers should perform such tests in practice at their own responsibility in case radioactive contamination is suspected in medicinal plants.
Residual Solvents
Only few organic solvents are used for the manufacture of herbal medicinal products. Except some individual cases, mainly ethanol and methanol are used, more rarely acetone, ethyl acetate, n-butanol, hexane and heptane. The International Conference on Harmonization (ICH) classifies organic solvents according to their potential risk into three classes. E.g., for methanol, a permitted daily exposure of 30 mg/day is given, for hexane of 2.9 mg/day. For the class with the lowest estimated risk, amounts of 50 mg/day or less would be acceptable without justification, higher amounts may also be acceptable provided they are realistic in relation to manufacturing capability and good manufacturing practice.
PROOF OF SAFETY AND EFFICACY
In principle, for all medicinal products pharmacological and toxicological examinations are requested, and efficacy has to be proven by clinical studies. The requirements for the proof of efficacy and safety are laid down in parts 3 and 4 of the Annex of Council Directive 2001/83/EC including the provisions for products with "wellestablished medicinal use."
In general, the toxicological and pharmacological tests must examine the potential toxicity of the product and any dangerous or undesirable toxic effects that may occur under the proposed conditions of use in human beings; these should be evaluated in relation to the pathological condition concerned; furthermore the pharmacological properties of the products, in both qualitative and quantitative relationship to the proposed use in human beings. All results must be reliable and of general applicability. Whenever appropriate, mathematical and statistical procedures shall be used in designing the experimental methods and in evaluating the results.
The clinical documentation consists of the conduct of trials (according to Good Clinical Practice), the presentation of results, e.g. the clinical observations, clinical pharmacology (pharmacodynamics, pharmacokinetics, interactions), bio-availability/ bioequivalence, clinical efficacy and safety and post-marketing experience.
For products with well-known active ingredients and a "well-established medicinal use", an option for a so-called "bibliographic application" instead of submission of new clinical and pharmacological/toxicological studies is provided by Article 10.1 a (ii) of Directive 2001/83/EC:
"The applicant shall not be required to provide the results of pharmacological and toxicological tests or the results of clinical trials if he can demonstrate ... that the constituent or the constituents of the medicinal product have a well established medicinal use, with recognised efficacy and an acceptable level of safety, by means of a detailed scientific bibliography."
Thus, for many herbal medicinal products, data from published literature may be used to substantiate safety and efficacy in expert reports and dossiers. In principle this system is suitable for herbal medicinal products as it is for all medicinal products containing well-known active substances. However, companies are still rather reserved using this procedure, due to the danger of different decisions of authorities which may lead to an arbitration procedure and result in negative decisions and a "negative rebound effect."
FIXED COMBINATIONS
Guidance on combinations of active ingredients is provided in the "Guideline on fixed combination products" issued by the Committee for Proprietary Medicinal Products (CPMP). As a general principle, applicants are required to justify the particular combination of active substances which is proposed. The presence of each active substance should make a contribution to the claimed effect, and potential advantages and disadvantages of the combination have to be assessed.
The EMEA Herbal Medicinal Products Working Party finalised a proposal for new guidance on "Fixed combinations of herbal medicinal products with long term marketing experience -Guidance to facilitate mutual recognition and use of bibliographic data". The principles are the same as outlined in the general guideline, taking into consideration the specific characteristics of herbal medicinal products.
HARMONIZATION OF ASSESSMENT CRITERIA
ESCOP, the European Scientific Cooperative on Phytotherapy, was founded in 18 1989 as an umbrella organisation of national scientific associations on phytotherapy.
Within its objective to establish harmonized criteria for the assessment of herbal medicinal products, ESCOP has prepared monographs on important plants and their medicinal use taking into consideration relevant scientific literature and different viewpoints from all countries involved. To be in line with the requirements laid down in European guidelines, and on the advice of the CPMP, the format of the Summary of Product Characteristics (SPC) was adopted for subsequent documentation as integral part of an application for marketing authorisation. An ESCOP monograph describing a medicinal plant and its preparations refers to a Pharmacopoeia monograph with respect to quality, and the most important constituents are listed which are possibly able to contribute to the claimed effect. The most relevant parts of the monographs (as for an SPC) are the therapeutic indications, the dosage and the pharmacological properties. The latter paragraph gives as many details as possible on pharmacodynamic properties, pharmacokinetic properties and preclinical safety data, each statement supported by references. The text is followed by a detailed reference list including all the papers that have been used for the evaluation of safety and efficacy of the respective medicinal plant and its preparations.
Six fascicules including a total of 60 monographs on efficacy and safety of medicinal plants and their preparations have been published, and further ones as well as revisions of the existing ones will be available in early summer of 2003. Table 1 shows the titles of all monographs included in the new publication.
In preparing drafts, the ESCOP Scientific Committee incorporates the views, knowledge and experience, not only of different nationalities, but also of individuals from different scientific and professional backgrounds, such as medical doctors, pharmacists, practising phytotherapists, pharmacognosists, pharmacologists and regulatory affairs specialists. The Committee assesses information from published scientific literature on each plant drug with the assistance of leading researchers on specific plants, who are invited to meetings of the Committee for discussion and critical evaluation of the literature.
Drafts prepared by the subcommittees are then circulated to an independent Board of Supervising Editors for appraisal. These academic experts in phytotherapy and medicinal plant research are invited to comment on and criticise each draft and, where appropriate, their comments are incorporated into the final version. Thus each ESCOP monograph takes into account the available scientific literature as well as national viewpoints and the advice of many authorities on the subject.
ESCOP monographs represent an overview on the current scientific data on a medicinal plant, but they cannot replace neither an expert report nor a documentation. They can be used as a "harmonized" scientific background for an application, whereas the questionnaire, i.e. the requirements of the expert report, has to be answered item by item by the applicant.
THE WHO TRADITIONAL MEDICINES PROGRAMME
Based on the "Guidelines for the Assessment of Herbal Medicines" which define basic criteria for the evaluation of quality, safety and efficacy of herbal medicines, WHO's Traditional Medicine Programme (TRM) has prepared a technical document entitled "Model Monographs of Widely used Medicinal Plants". These monographs include summaries of the botanical characteristics and chemical constituents as well as clinical applications, pharmacology, posology, contraindications and adverse reactions. Two volumes, each consisting of approx. 30 model monographs have already been published, and a third and forth volume are in preparation.
THE EMEA HERBAL MEDICINAL PRODUCTS WORKING PARTY
The Herbal Medicinal Products Working Party (HMPWP) established in 1997 consists of representatives from the Member States (primarily health authorities) and from the European Parliament, the European Commission and the European Pharmacopoeia.
Since its foundation the group has reviewed the criteria for the demonstration of quality, pre-clinical safety and clinical efficacy in marketing authorisation applications for herbal medicinal products as set out in the Council Directives. In particular, it has completely revised the guidance provided in "Quality of Herbal Remedies" (now called "Quality of Herbal Medicinal Products"), taking into consideration that herbal medicinal products and their raw materials are complex mixtures. The group has also proposed requirements for non-clinical testing of herbal drug preparations based on a draft EC Guideline for old substances with long market histories, and a lot of further papers.
Furthermore, the group has discussed the role of scientific monographs and expressed its opinion that those drafted by ESCOP and WHO "offer a valuable and updated overview on published scientific literature, which together may be used in support of the demonstration of the safety and efficacy of a medicinal product". The group has started evaluating these monographs in order to develop official assessment criteria for herbal medicinal products that can be used by authorities as well as by industry to apply for marketing authorisations. After publication of a so-called "core-SPC" on Valerianae radix, draft core data on 11 medicinal plant preparations were released for consultation in 2003.
THE NEW DRAFT DIRECTIVE ON TRADITIONAL HERBAL MEDICINAL PRODUCTS
Besides the bibliographic application for products with a "well-established medicinal use" and on a lower level regarding scientific evidence, a new draft Directive on traditional herbal medicinal products is available. It includes -as a further option -a specific registration system for traditional herbal medicinal products. Those herbal medicinal products which can be authorised under the existing Directives (either on the basis of the results of tests on safety and efficacy or on the basis of reference to published scientific literature) shall not be eligible for this simplified registration.
Several conditions have to be fulfilled to be eligible for a registration under the new Directive, e.g., specific indication claims (without intervention of a practitioner) and a specified strength; oral, external or inhalation preparation. Harmful products will be excluded. The pharmacological effects and/or the efficacy must be plausible. An important criterion to assess whether or not a product will be suitable for registration under the new provisions is a 30-year use within the Community. If the product has been available within the Community for at least 15 years (or, according to recent debates, perhaps 10 years), it appears acceptable to the Commission that the evidence of 30 years of medicinal use may fully or partly relate to such use outside the Member States.
Regarding the quality dossier, in principle the same particulars and documents have to be provided as for all other applications under Directive 2001/83/EC. Information addressed to the public shall contain a statement that the product is a traditional herbal medicinal product and that the efficacy has not been proven.
Furthermore, a new Committee for Herbal Medicinal Products will be set up within the EMEA in order to ensure full participation and involvement of experts in the field of herbal medicinal products. This new Committee will replace the current Herbal Medicinal Products Working Party (HMPWP), whose status will be upgraded to that of a "Committee" and whose tasks will relate to the scientific issues with regard to the herbal medicinal products and herbal substances. The Committee will be composed of one member nominated by each Member State with regard to their special role and experience for a 3-year term which is renewable.
One of the major tasks of the new Committee will be to establish Community herbal monographs. The new provisions state that these monographs will be relevant for the assessment of an application for a marketing authorisation based on well-established medicinal use as well as of an application for registration of traditional herbal medicinal products. When new monographs are adopted, the registration holder will be obliged to introduce a modification to the registration dossier so as to comply with the new monographs.
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Another task of the Committee shall be to set up a list of herbal substances that fulfil the conditions of eligibility for the registration procedure. For each substance, the list will indicate the therapeutic indication, the specified strength, the route of administration and any other relevant safety information. If an application for traditionaluse registration refers to a herbal substance contained in that list, the applicant, instead of supplying the respective documents, may refer to the contents of the list.
The new Directive, which will be an amendment to the existing Directive 2001/83/EC, is expected to be finally adopted approx. mid of 2003, followed by official publication and entry into force after that date. The Directive will be addressed to the Member States of the European Union which shall take the measures necessary to comply with the provisions by 31 December 2004. For traditional herbal medicinal products which are already in the market when the provision become effective, a transition period of five years shall apply.
FUTURE PERSPECTIVES
In the area of the "well-established medicinal use" creation of further "core data" by the HMPWP is highly appreciated because this might facilitate a mutual recognition of marketing authorisation decisions in the decentralised procedure.
The proposed Directive on traditional medicinal products is appreciated for those products which do not fulfill the criteria of the "well-established medicinal use". However, monographs like those compiled by ESCOP represent a summary of the available evidence, taking into account all available scientific literature and therefore being suitable for bibliographic applications. For this reason it is regarded to be of vital importance that the well-established medicinal use category for herbal medicinal products is maintained as a basis for marketing authorisations. The 'traditional' list should thus only apply to products for which well-established medicinal use cannot be demonstrated.
The new Committee should be responsible for all kinds of herbal medicinal products, well-established products including those with clinical studies as well as traditional products. The Committee should form an independent group within the EMEA and also be responsible for arbitration procedures. The goal of all these activities should be a harmonised and appropriate assessment of all herbal medicinal products in Europe.
